S.Biomedics Co., Ltd. (KOSDAQ:304360)
South Korea · Delayed Price · Currency is KRW 31,450
+1,650 (5.54%)
At close: Jun 12, 2026
S.Biomedics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -8,221 | -8,122 | -6,691 | -10,321 | -6,327 | -5,667 |
Depreciation & Amortization | 2,259 | 2,043 | 1,725 | 1,553 | 1,517 | 1,448 |
Loss (Gain) From Sale of Assets | - | - | - | -5.49 | - | - |
Loss (Gain) From Sale of Investments | -78.26 | -105.87 | -25.23 | -51.81 | -6.77 | -0.24 |
Stock-Based Compensation | 523.4 | 442.35 | 55.38 | 86.21 | 148.08 | 217.39 |
Provision & Write-off of Bad Debts | 234.46 | 272.84 | 12.67 | 174.99 | -160.05 | -188.31 |
Other Operating Activities | -713.49 | 482.88 | 1,856 | 4,564 | 3,105 | 1,666 |
Change in Accounts Receivable | -935.47 | -155.49 | 201.51 | -771.8 | -697.48 | 440.6 |
Change in Inventory | 506.35 | 462.02 | 71.14 | -830.05 | -817.71 | -204.21 |
Change in Accounts Payable | -169.82 | 190.22 | -292.73 | 63.31 | 379.86 | -423.02 |
Change in Other Net Operating Assets | -669.92 | 509.85 | -413.31 | -610.69 | -347.05 | -576.36 |
Operating Cash Flow | -7,264 | -3,981 | -3,500 | -6,149 | -3,205 | -3,287 |
Capital Expenditures | -4,672 | -4,604 | -1,390 | -1,847 | -9,295 | -474.49 |
Sale of Property, Plant & Equipment | - | - | - | 22.14 | - | - |
Sale (Purchase) of Intangibles | -15 | -15 | -324.4 | - | -149.39 | -15.8 |
Investment in Securities | 10,690 | 10,582 | -8,547 | -6,655 | 2,708 | -3,445 |
Other Investing Activities | 81.63 | -563.05 | -86 | -343.25 | -43.69 | -64.87 |
Investing Cash Flow | 6,085 | 5,400 | -10,348 | -8,824 | -6,871 | -3,990 |
Long-Term Debt Issued | - | 6,300 | 11,775 | - | 7,000 | 4,860 |
Total Debt Issued | 6,300 | 6,300 | 11,775 | - | 7,000 | 4,860 |
Long-Term Debt Repaid | - | -7,780 | -2,573 | -1,156 | -732.69 | -1,061 |
Total Debt Repaid | -7,668 | -7,780 | -2,573 | -1,156 | -732.69 | -1,061 |
Net Debt Issued (Repaid) | -1,368 | -1,480 | 9,202 | -1,156 | 6,267 | 3,799 |
Issuance of Common Stock | 807.59 | 1,653 | 7,574 | 14,282 | - | - |
Other Financing Activities | -0 | -0 | 133.5 | -808.56 | 852.9 | 362.18 |
Financing Cash Flow | -560.86 | 173.39 | 16,909 | 12,318 | 8,020 | 4,161 |
Foreign Exchange Rate Adjustments | 26.44 | 8.34 | 11.89 | -0.86 | -9.47 | 59.35 |
Net Cash Flow | -1,714 | 1,601 | 3,074 | -2,656 | -2,066 | -3,057 |
Free Cash Flow | -11,936 | -8,584 | -4,890 | -7,996 | -12,501 | -3,762 |
Free Cash Flow Margin | -72.42% | -51.88% | -35.61% | -61.00% | -103.20% | -42.42% |
Free Cash Flow Per Share | -991.97 | -722.99 | -425.15 | -731.44 | -1223.19 | -370.56 |
Cash Interest Paid | 373.84 | 363.82 | 426.59 | 487.05 | 156.16 | 158.4 |
Cash Income Tax Paid | 164.94 | 176.06 | 78 | 31.47 | 3.22 | -20.09 |
Levered Free Cash Flow | -10,205 | -3,508 | -4,647 | -8,051 | -9,322 | -3,057 |
Unlevered Free Cash Flow | -9,298 | -2,602 | -4,150 | -7,499 | -8,867 | -2,636 |
Change in Working Capital | -1,269 | 1,007 | -433.4 | -2,149 | -1,482 | -762.99 |